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Tilting disc and stented porcine 19-mm valves have
both shown poor hemodynamic performance in the
aortic position.1,6,11,13 On the other hand, bileaflet
valves are still the most implanted cardiac valve sub-
stitutes in the aortic position. Their excellent durabil-
ity and low incidence of cardiac-related complica-
tions have been widely reported in the medical
literature.1,5,14,15
Although valve manufacturers have recently im-
proved hemodynamic performances of small aortic
prostheses, the implantation of small-valve prostheses
in the aortic position is still considered to imply the risk
of high residual gradients.5,6,15,16
The purpose of this retrospective study is to evaluate
and compare the clinical and hemodynamic perfor-
mance of 19-mm St Jude Medical Hemodynamic Plus
(HP) and Standard valves (St Jude Medical, Inc, St
Paul, Minn) implanted in the aortic position.
The replacement of the aortic valve with any kind ofdevice implies the acceptance of a residual gradi-
ent.1-3 The use of an aortic valve prosthesis in the small
anulus raises concerns about the harmful effects of
residual obstruction to left ventricular outflow.4-7
Residual gradient is the driving stimulus for incomplete
regression of left ventricular hypertrophy after aortic
valve replacement (AVR), and it has been related to
higher long-term incidence of cardiac complications
and mortality.8-11 An indexed orifice area of less than
0.9 cm2/m2 has been associated with a higher incidence
of late complications, including sudden death.3,12
Objective: We reviewed our experience with aortic valve replacement using
19-mm St Jude Medical prostheses (St Jude Medical, Inc, St Paul, Minn) in
119 patients, among which 68 (group A) had a Standard model and 51
(group B) had a Hemodynamic Plus model.
Methods: Comparison between the 2 models included analysis of early and
late mortality and all valve-related complications. Postoperative echo-
cardiography was performed to evaluate the hemodynamic performance of
both prosthetic models. Laboratory tests were performed to evaluate the
amount of red blood cell damage caused by the transprosthetic turbulent
flow.
Results: Average body surface area was 1.66 ± 0.14 m2 in group A and 1.65
± 0.16 m2 in group B (P = .72). There was no statistically significant differ-
ence between the 2 groups in terms of preoperative variables (sex, cardiac
rhythm, body surface area, preoperative gradients, and New York Heart
Association class). Five-year follow-up was 100% complete. Although
group A patients had significantly higher postoperative peak and mean gra-
dients (P = .0001) and a lower effective orifice area (P = .0001), no statisti-
cal differences were found in terms of late (5-year) survival (P = .6) and
postoperative complications (P = .09). Moreover, postoperative left ventric-
ular mass was found to be similar in the 2 groups (P = .18). Hematologic
evaluation did not show any significant difference between the 2 groups as
to incidence of hemolysis.
Conclusions: Aortic valve replacement with 19-mm aortic prostheses in
patients with a body surface area of less than 1.7 m2 allows good results.
Although Hemodynamic Plus models have better hemodynamic results, no
significant difference was found in terms of clinical results and clinical
hemolysis. (J Thorac Cardiovasc Surg 2001;121:723-8)
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Materials and methods
Between January 1983 and December 1997, 119 isolated
19-mm St Jude Medical bileaflet aortic prostheses were
implanted at our institution. Patients were distributed into 2
groups according to the prosthesis model: group A included
68 patients with the Standard model, and group B included
51 patients with the HP model. Preoperative clinical and
echocardiographic data are reported in Tables I and II,
respectively. 
Patients. Patient selection was not randomized; the St Jude
Medical HP valve has been available in our institution since
1994, and therefore the majority of group A patients were
operated on earlier than group B patients. All patients had
aortic stenosis; concomitant aortic regurgitation was observed
in 10 (14.7%) patients undergoing AVR with the Standard
prosthesis and in 11 (21.6%) undergoing AVR with the HP
model (P = .46). Patients with associated procedures for coro-
nary artery disease, mitral valve disease, and/or discrete sub-
valvular aortic stenosis were excluded from the study.
Furthermore, to avoid any interference between valve-related
hemolysis and red blood cell damage caused by other dis-
eases, patients with more than moderate tricuspid regurgita-
tion; hepatic disease, renal disease, or both; or any kind of
hematologic disorder were excluded.
Surgical procedure. After median sternotomy, all patients
underwent AVR with a 19-mm mechanical bileaflet prosthe-
sis under mild hypothermic cardiopulmonary bypass.
Myocardial protection was achieved both with topical
hypothermia and with intermittent infusion of cold crystal-
loid solution (St Thomas’ Hospital) directly into the coronary
ostia. The procedure was always performed by the same
group of surgeons.12 Aortic prostheses were implanted in the
intra-annular position with nonpledget-supported simple
interrupted sutures (Tevdek 2-0; Deknatel, Inc, Fall River,
Mass). The hinge area was positioned at 90° with the inter-
ventricular septum. By policy, in our experience an associate
patch enlargement of the aortic anulus was considered only in
patients with an expected indexed effective orifice area
(IEOA) of less than 0.9 cm2/m2.
Anticoagulation protocol. All patients were treated with
oral anticoagulation, which was carried out in all cases with
warfarin sodium. Ninety percent of our patients were fol-
lowed up in our anticoagulation clinic. The others were
referred to a satellite institution following the same anticoag-
ulation protocol as our center. Prothrombin activity was kept
between 25% and 35%, which equals an international nor-
malized ratio ranging between 2.0 and 3.5.
Clinical evaluation and definition of complications.
Patients operated on in our institution are commonly seen at
least yearly in our outpatient clinic where they undergo clin-
ical examination (including blood pressure measurement)
and, when indicated, echocardiographic study. Hospital
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Table I. Preoperative clinical and echocardiographic data
Group A Group B P value
No. of patients 68 51
Age (y) 65.15 ± 11.41 63.04 ± 13.12 .5
Sex (M/F) 20/48 20/31 .36
Preoperative ECG rhythm 66 SR 49 SR .81
Mean BSA, m2 (range) 1.66 ± 0.14 (1.4-1.69) 1.65 ± 0.16 (1.36-1.69) .72
Ascending aortic diameter (mm) 29.33 ± 3.5 30 ± 3.5 .8
Max gradient (mm Hg) 92.11 ± 23.06 85.14 ± 22.1 .5
Mean gradient (mm Hg) 54.6 ± 15.9 51.33 ± 16.7 .7
NYHA class 2.41 ± 0.4 2.47 ± 0.5 .8
Total length of follow-up (mean in mo) 4739 (77.69 ± 35.04) 1406 (28.12 ± 14.95) .0001*
SR, Sinus rhythm; NYHA, New York Heart Association. 
*Statistically significant difference.
Table II. Late echocardiographic data
Echocardiographic parameters Group A (n = 58) Group B (n = 49) P value
EF (%) 57 ± 7 61 ± 7 .004*
Peak gradient (mm Hg) 53.85 ± 7.16 32.78 ± 11.72 .0001*
Mean gradient (mm Hg) 34.80 ± 5.55 19.11 ± 8.85 .0001*
Interventricular septum (mm) 12.2 ± 3.8 12.6 ± 1.6 .493
Posterior wall (mm) 7.6 ± 5.9 12.5 ± 0.6 .0001*
Ascending aortic diameter (mm) 31.0 ± 4.5 33.8 ± 8.0 .026*
EOA (cm2) 1.93 ± 0.05 2.02 ± 0.06 .0001*
IEOA (cm2/m2) 1.17 ± 0.04 1.21 ± 0.05 .0001*
LVM (g) 236 ± 53 216 ± 46 .04*
Indexed LVM (g/m2) 142 ± 45 131 ± 38 .18
EF, Ejection fraction. 
*Statistically significant difference.
records were checked retrospectively to achieve hospital mor-
tality and morbidity data. No patient was lost to follow-up.
Cumulative mortality and morbidity was labeled as “treat-
ment failure” (including hospital mortality, late mortality, and
all valve-related complications).17,18
Echocardiographic study. All surviving patients under-
went M-B mode color Doppler echocardiographic evaluation
preoperatively and during the follow-up period. Postoperative
echocardiography was performed every 6 months.
The modified Bernoulli equation was used to calculate the
instantaneous pressure gradients across the prosthesis. The
velocity in the left ventricular outflow tract (LVOT) was con-
sidered in gradient calculation by including it in the equation.
The mean pressure gradient was calculated by averaging the
gradient at 40-ms intervals throughout the velocity complex-
es. Peak velocity measurements were performed with a
pulsed wave Doppler echocardiographic scanner by using the
lower angle as soon as possible. The peak velocity was
obtained by averaging from 3 measured velocities. Velocities
across the prosthesis were recorded a few minutes after the
end of the exercise because at this time the peak flow veloci-
ty reaches its highest level. The effective orifice area (EOA)
of the prosthesis was calculated with the following continuity
equation by mean of the simplified peak velocity method:
EOA = CSA (PkVLVOT/PkVjet)
where CSA is the cross-sectional area of the LVOT, and
PkVLVOT and PkVjet are the maximal velocity in the LVOT
and across the valve, respectively. This simplified method has
shown a good correlation with that of the original continuity
equation. Furthermore, the cross-sectional area of the LVOT
was determined by assuming that the sewing ring size was the
cross-sectional diameter of the LVOT.
In all cases the IEOA (IEOA = EOA/BSA [body surface
area]) and indexed left ventricular mass (LVM) were calcu-
lated. BSA was calculated according to the formula of
Dubois.
Hematologic evaluation of hemolysis. All patients were
informed about the purpose of the study, and all of them gave
written consent. A 20-mL blood sample was taken every
week for 2 weeks to perform the following measurements: (1)
blood hemoglobin (in grams per deciliter); (2) serum lactic
dehydrogenase (in units per liter); (3) percent-correlated
reticulocyte fraction; (4) serum haptoglobin (in grams per
liter); and (5) schistocytes (percent). The data were recorded,
and the final results were expressed as the mean value of the
2 blood tests.
The criteria proposed by Skoularigis and colleagues19 were
used to define hemolysis. Patients were considered as having
intravascular hemolysis when serum lactic dehydrogenase
(LDH) levels were elevated (>460 U/L, major criteria) and at
least 2 of the following minor criteria were observed:
• blood hemoglobin of less than 13.8 g/dL for male
patients and less than 12.4 g/dL for female patients;
• reticulocyte fraction of greater than 2%;
• presence of schistocytes in the blood; and
• serum haptoglobin level of less than 0.5 g/L.
Statistical analysis. Statistical analysis was performed
with the SPSS statistical software package (SPSS, Inc,
Chicago, Ill). Categoric values of the 2 groups were com-
pared by using the χ2 or Fisher exact tests, whereas continu-
ous data, reported as means ± SD, were compared by using
the Student t test. Time-related analysis of late complications
was calculated as the percentage of events per year.
Univariate survival and actuarial analysis were performed




Hospital mortality. A total of 8 (6.7%) patients died
during their hospital stay; 7 (10.3%) belonged to group
A, and 1 (2%) belonged to group B (P = .153). Causes
of death were low output syndrome in 6 patients (5
patients of group A and 1 patient of group B; P = .08),
mediastinitis in 1 patient, and disseminate intravascular
coagulopathy in 1 patient.
Late mortality. Four patients died during the follow-
up; 3 (4.9%) of them had a Standard model prosthesis
(group A), and 1 (2%) had an HP model prosthesis
(group B) (P = .757). Causes of late death were sudden
death in 2 patients, both belonging to group A
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Fig 1.  Freedom from treatment failure in the 2 groups of patients with 19-mm St Jude Medical aortic prostheses.
(transprosthetic mean gradients at the last echocardio-
graphic control were 25 and 35 mm Hg, respectively);
cancer in 1 patient; and road accident in 1 patient. Five-
year actuarial survival did not show any significant dif-
ference between the 2 groups (group A, 93.4% ± 4%;
group B, 96.15% ± 37%, P = .6; 13-year actuarial sur-
vival in group A was 90.89% ± 6%).
Clinical status. Mean New York Heart Association
class at latest follow-up was 1.2 ± 0.7 in group A ver-
sus 1.1 ± 0.6 in group B (P = .14). There was no sta-
tistical difference between the 2 groups in terms of
peripheral blood pressure (group A: mean systolic
pressure of 145 ± 15 mm Hg and mean diastolic pres-
sure of 80 ± 10 mm Hg; group B: mean systolic pres-
sure of 140 ± 20 mm Hg and mean diastolic pressure
of 75 ± 10 mm Hg) at follow-up. Moreover, there was
no statistical difference between the 2 groups in
terms of requirement of cardiovascular drugs (group
A, 40/61 [65.6%] patients; group B, 32/50 [64%]
patients).
Embolism. There was no statistical difference
between rates of freedom from embolism in the 2
groups at 5 years of follow-up. No case of embolism
was observed in any group of patients (100% event
free) within the first 5 years of follow-up. Two patients
of group A had a neurologic complication caused by
embolism after the fifth postoperative year, resulting in
a 13-year event-free rate of 89.41% ± 7%.
Hemorrhage. No case of hemorrhage was observed
in patients with HP prostheses (100% event free). One
patient with the Standard 19-mm prosthesis had gastric
bleeding that required blood transfusion (13-year free-
dom from hemorrhage in group A, 98.25% ± 2%). No
statistical difference was found between the 2 groups at
5 years of follow-up.
Endocarditis, thrombosis, and reoperation. No cases
of endocarditis, prosthetic thrombosis, and reoperation
have been reported during the follow-up.
Treatment failure. Cumulative analysis of events,
including early and late mortality and all valve-related
complications, did not show any statistically significant
difference at 5 years of follow-up (group A, 89.25% ±
7%; group B, 93.24% ± 5%; P = .09). Thirteen-year
freedom from treatment failure in group A was 73.27%
± 9% (Fig 1).
Echocardiographic results. Late echocardio-
graphic results are reported in Table II. Significantly
lower mean (19.11 ± 8.85 mm Hg) and peak gradi-
ents (32.78 ± 11.72 mm Hg) were observed in
patients with the St Jude Medical HP prosthesis ver-
sus the Standard prosthesis (mean gradient, 34.80 ±
5.55 mm Hg; peak gradient, 53.85 ± 7.16 mm Hg; 
P = .001). EOA was statistically higher (P = .0001)
in patients with HP heart valve prostheses (2.02 ±
0.06) versus Standard St Jude Medical prostheses
(1.93 ± 0.05). Similar data were observed in the
analysis of the IEOA (Table II). No statistical differ-
ence (P = .18) was observed between the mean LVM
of the HP prosthesis group (131 ± 38 g) and that of
the Standard prosthesis group (142 ± 45 g).
Hematologic results. No pathologic levels of serum
haptoglobin, reticulocytes, and schistocytes were
observed in both groups. Haptoglobin levels and percent-
corrected reticulocyte fractions were statistically lower in
patients with the Standard prosthesis (Table III). The
mean count of schistocytes was statistically lower (P =
.005) in patients with the HP prosthesis (Table III).
The mean LDH value was high (>460 U/L) in both
groups; the mean LDH value of 580 ± 58 U/L, which
was observed in group B patients, was statistically
lower than 610 ± 62 U/L, which was observed in
patients with Standard prostheses (P = .011, Table III).
Low levels of blood hemoglobin (13.7 ± 1.6 g/dL in
group B patients and 13.4 ± 1.4 g/dL in group A
patients) were found (P = not significant). 
According to the criteria19 previously reported, 14
(24.14%) of 58 group A patients and 13 (26.5%) of 49
group B patients showed some degree of intravascular
hemolysis (P = not significant, Table III).
Discussion
The objective of AVR is to restore valvular function
with the lowest transprosthetic gradient. To improve
hemodynamic performances of aortic valve prostheses,
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Table III. Hematologic results (evaluation of hemolysis)
Group A Group B P value
Hemolysis 14/58 (24.14%) 13/49 (26.53%) .993
Serum haptoglobin (g/L) 1.8 ± 0.2 2.2 ± 0.5 .0001*
Reticulocytes (%) 0.5 ± 0.5 1.2 ± 0.21 .0001*
Schistocytes (%) 1.1 ± 0.4 0.9 ± 0.3 .005*
LDH (U/L) 610 ± 62 580 ± 58 .011*
Blood hemoglobin (g/dL) 13.4 ± 1.4 13.7 ± 1.6 .299
*Statistically significant difference.
new models of bileaflet valves have been devised, reduc-
ing the suture cuff.6,15 At the same time, stentless porcine
valves have been commercialized to minimize transpros-
thetic gradients.9,10,20 In patients with stentless valves,
minimal transprosthetic gradients and almost complete
LVM regression have been reported.9,20
In the early decades of cardiac operations, hemody-
namic evaluation of mechanical aortic prostheses was
almost impossible.21-23 Surgeons used to evaluate
transprosthetic gradients intraoperatively.
Doppler ultrasonography–measured pressure gradi-
ents across different types of bioprosthetic and
mechanical valves are reported to correlate well with
catheter-derived gradients.24-26 Although bileaflet
valves have a central flow and should allow an accurate
measurement of gradients, the presence of pressure
recovery and high localized pressure gradients might
cause some overestimation compared with the catheter
pressure gradient, as found by Baumgartner and asso-
ciates26 in St Jude Medical valves. The results of a
proper match between patients and prostheses can be
evaluated by means of echocardiography through ven-
tricular mass regression.2,9,12,13
Nowadays, assessment of bileaflet valve perfor-
mances must include clinical and echocardiographic
studies. In addition, high gradients and flow turbulence
have been associated with significant hemolysis.19,27,28
Many studies, in which the performances of different
aortic valve prostheses were evaluated, have emphasized
that successful AVR should achieve an indexed valve area
greater than 0.9 cm2/m2 to minimize prosthetic gradients
and obtain postoperative LVM regression.3,8,11,12
Therefore, there are some controversies about the
long-term effect of residual transprosthetic gradient in
patients with a small aortic anulus and an expected
IEOA greater than 0.9 cm2/m2. Furthermore, the advan-
tages and the intermediate-term results of new and
improved orifice models are still to be fully assessed.
Transprosthetic gradients are correlated to cardiac
output and BSA. The BSA of Mediterranean patients
older than 60 years referred for AVR averages 1.66 m2.
In our study, a critical value of IEOA of less than 0.9
was not observed in any patient.
This study confirms that as long as the EOA of
bileaflet aortic valve implanted in adult patients with
normal body size is greater than 0.9 to 1 cm2/m2, hemo-
dynamic performances are good, and long-term clinical
results are excellent. Hachida and colleagues,29
although studying a group of patients with smaller
BSAs than ours and with pure aortic stenosis alone,
reported postoperative results that are consistent with
our findings as far as peak and mean gradients and
postoperative indexed LVM are concerned, particularly
in patients with HP models. However, we could not
explain the discrepancy between that study and ours in
the postoperative EAO of both Standard and HP valves.
In no study have HP valves, despite their better hemo-
dynamic results, been shown to significantly improve
clinical results. However, a 91% survival at 13 years in
patients with Standard model prostheses and a mean
age of 65 years is already a good result when compared
with other recent series.30,31
This study analyses our 16-year experience with 19-
mm Standard and HP St Jude Medical aortic prostheses
retrospectively. A retrospective analysis of such a wide
time period may imply limitations related to changes in
diagnostic, operative, or both types of technologies and
techniques. Length of follow-up is different between
the 2 groups because HP models have been available in
our institution since 1994. However, the longer follow-
up belongs to the model that has worse hemodynamic
performances. Moreover, time-related analysis of
events was truncated at 5 years for both groups to
achieve comparable data. Although in our study no sig-
nificant difference between the 2 groups of patients
was found in terms of late survival, it must be pointed
out that most of the patients from group B have not yet
reached 4 years of follow-up. No LVM regression
analysis was performed because such data have been
available in our institution only in recent years.
Another limitation to our study can be represented by
the mean age of patients because a lower physical
activity is expected in patients older than 60 years.
It must be pointed that because bileaflet valves in the
aortic position usually carry low degrees of hemolysis,19
differences between similar models can be difficult to
ascertain with the common hematologic tests.28 The cri-
teria of Skoularigis and colleagues19 have been proven to
be effective in evaluating the amount of intravascular
hemolysis and to perform comparisons between differ-
ent models of mechanical valves. Nevertheless, accord-
ing to such criteria, no significant difference between the
HP and Standard series was found as to late postopera-
tive intravascular hemolysis, although mean LDH serum
levels and schistocyte count were significantly lower in
group B. It can be stated that subclinical blood cell dam-
age could be significantly higher in patients with stan-
dard 19-mm aortic prostheses compared with those
receiving HP prostheses.
In conclusion, our study confirms that 19-mm
bileaflet aortic valves allow good long-term clinical
results and acceptable hemodynamic results in
patients with a BSA of less than 1.7 m2. Improved
orifice models allow lower gradients, but such data
do not affect clinical results and the amount of red
blood cell damage.
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